Recruiting

Observational Study

Sponsor:

Marc Toeteberg-Harms

Code:

NCT07510087

Conditions

Glaucoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

GQL-15

Glaucoma Symptom Scale

NEI Vision Function Questionnaire

Ocular Surface Disease Index

Study Details

Brief summary:

Subjects with a diagnosis of glaucoma will be handed out different quality of life related questionnaires and their score will be evaluated at baseline and 3-6 months after treatment or surgery was initiated/performed.

Conditions

Glaucoma

Study ID

NCT07510087

Start date

Dec 30, 2024

Status verified date

Apr, 2026

Completion date

May 30, 2027

Anticipated

Primary completion date

Nov 30, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion:

  • diagnosis of glaucoma (open- as well as closed-angle glaucoma, primary and secondary glaucomas)
  • 18 years of age or older with no upper limit
  • male and female subjects

Exclusion:

  • absence of a diagnosis of glaucoma
  • less than 18 years of age

Study Design

Enrollment

5000 participants

Anticipated

Interventions and Outcome Measures

Arms

Study Arm (glaucoma)

subjects with a diagnosis of glaucoma

Interventions

GQL-15

GQL-15 questionnaire

Glaucoma Symptom Scale

GSS questionnaire

NEI Vision Function Questionnaire

Vision function questionnaire

Ocular Surface Disease Index

OSDI questionnaire

Primary outcome measure

  • Ocular Surface Disease Index (OSDI) [ Time Frame: At baseline and 3-6 months after glaucoma treatment (i.e. drops, SLT, or surgery) was initiated/performed. ]
  • Glaucoma Symptom Scale (GSS) [ Time Frame: At baseline and 3-6 months after glaucoma treatment (i.e. drops, SLT, or surgery) was initiated/performed. ]
  • National Eye Institute Visual Function Questionaire (NEI VFQ) [ Time Frame: At baseline and 3-6 months after glaucoma treatment (i.e. drops, SLT, or surgery) was initiated/performed. ]
  • Glaucoma Quality of Life-15 (GQL-15) [ Time Frame: At baseline and 3-6 months after glaucoma treatment (i.e. drops, SLT, or surgery) was initiated/performed. ]

Central Contacts and Locations

Central contacts

Marc Toeteberg-Harms, MD

+1 319 356 3938marc-toeteberg-harms@uiowa.edu

Helen Gomez Study Coordinator

+1 319 356 3938helen-gomez@uiowa.edu

Locations

University of Iowa, Dept. of Ophthalmology & Visual Sciences

Recruiting

Iowa City, Iowa, United States, 52242

Contacts

Marc Toeteberg-Harms, MD

+1 319 356 3938marc-toeteberg-harms@uiowa.edu

Helen Gomez

+1 319 356 3938helen-gomez@uiowa.edu

Principal Investigator:

Marc Toeteberg-Harms, MD

More Information

Sponsor

Marc Toeteberg-Harms

Last update posted

Apr 6, 2026

Last verified

Apr, 2026

Keywords

  • glaucoma
  • quality of life

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Marc Toeteberg-Harms on 2026-04-06.